Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 4/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071053 | 1.00 | BACE1 (0.64) | BACE1HDAC2APPTTRCYP2A6 | |
| SCHEMBL29820553 | 0.88 | APP (0.64) | BACE1HDAC2APPTTRCYP2A6 | |
| SCHEMBL2508820 | 0.88 | APP (0.64) | BACE1HDAC2APPTTRCYP2A6 | |
| SCHEMBL2508821 | 0.88 | APP (0.64) | BACE1HDAC2APPTTRCYP2A6 | |
| SCHEMBL18255132 | 0.85 | CCNC (0.59) | BACE1HDAC2TTRCYP2A6CA12 | |
| SCHEMBL3214676 | 0.83 | BACE1 (0.72) | BACE1HDAC2APPCYP2A6CA12 | |
| SCHEMBL4590213 | 0.83 | BACE1 (0.57) | BACE1HDAC2APPCYP2A6MAPT | |
| SCHEMBL4590217 | 0.83 | BACE1 (0.57) | BACE1HDAC2APPCYP2A6MAPT | |
| SCHEMBL3214658 | 0.83 | BACE1 (0.72) | BACE1HDAC2APPCYP2A6CA12 | |
| SCHEMBL6615607 | 0.83 | BACE1 (0.58) | BACE1HDAC2APPCYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| CN-108440370-B | Inhibitors of viral replication | 鲁汶天主教大学 | 2021-07-30 | — | — | CN | disclosed |
| EP-3617192-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10550123-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2020-02-04 | — | — | US | disclosed |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2019-11-07 | — | — | US | disclosed |
| EP-2760831-B1 | VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2019-08-07 | — | — | EP | disclosed |
| CN-104024223-A | Inhibitors of viral replication | UNIV LEUVEN KATH | 2014-09-03 | — | — | CN | disclosed |
| EP-2760831-A1 | VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2014-08-06 | — | — | EP | disclosed |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-07-31 | — | — | US | disclosed |
| WO-2013045516-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2013-04-04 | — | — | WO | disclosed |
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-19 | — | — | US | disclosed |
| EP-1397136-A1 | HETEROCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2002096424-A1 | HETEREOCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | CA3, GAP43, SLC1A2 | BACE1 219/4885HDAC2 1394/4885APP 213/4885 |
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | GAP43, GABRE, CA3 | BACE1 84/4885HDAC2 1199/4885APP 124/4885 |
| US-20140213586-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | BACE1 2559/4885HDAC2 980/4885APP 2827/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | BACE1 2559/4885HDAC2 980/4885APP 2827/4885 |
| US-20190337954-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | BACE1 2559/4885HDAC2 980/4885APP 2827/4885 |
| US-10550123-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | BACE1 2559/4885HDAC2 980/4885APP 2827/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | BACE1 2559/4885HDAC2 980/4885APP 2827/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | BACE1 2559/4885HDAC2 980/4885APP 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.